Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 4/20 | 0.48 |
| ▸ | PIP4K2B | P78356 | 4/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | PIK3C3 | Q8NEB9 | 7/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4511353 | 0.85 | PIK3C3 (0.52) | PIK3CBPIK3C3PIK3CDPIK3CAPIK3CG | |
| SCHEMBL4512813 | 0.81 | ACLY (0.43) | PIP4K2APIP4K2BPIK3C3PIK3CA | |
| SCHEMBL4519803 | 0.81 | PIK3CA (0.40) | PIP4K2APIP4K2BPIK3CBPIK3C3DYRK1A | |
| SCHEMBL3972385 | 0.79 | ADORA2A (0.37) | PIK3C3DYRK1APIK3CGAOC3 | |
| SCHEMBL3972288 | 0.79 | PTGS2 (0.38) | PIK3C3PIK3CGAOC3 | |
| SCHEMBL4506432 | 0.75 | RAB9A (0.40) | PIK3C3 | |
| SCHEMBL4506437 | 0.74 | HCRTR1 (0.33) | PIK3C3DYRK1A | |
| SCHEMBL10369 | 0.74 | CYP1A2 (0.56) | CYP11B2PIK3CAPIK3CG | |
| SCHEMBL8212993 | 0.72 | PIK3CA (0.54) | PIP4K2APIP4K2BPIK3CBPIK3C3PIK3CD | |
| SCHEMBL3973580 | 0.70 | ADORA1 (0.37) | PIK3C3AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118336-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118336-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MTOR, RICTOR, PIK3R5 | PIP4K2A 40/4885PIP4K2B 35/4885PIK3CB 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.